AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01042054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wound catheter plus patient-controlled analgesia.
Description: * Continuous infusion of local anaesthetic administered via wound catheters for the first 48 hours postoperatively.~* Additional patient-controlled intravenous opiate analgesia available to patient during this time period.~* Sham epidural catheter applied to the patient's back for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout.
Study NCT02987244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Six cycles of therapy will be administered,and each cycle of treatment is 28 days.~Phase I: Patients were treated at the following dose levels: 15, 20, and 25 mg twice per week to determine the MDT Phase II: If MTD was not reached at 25mg dose level of Chidamide. The followed study will use 20mg twice per week as experimental dose.
Study NCT02987244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide(750mg/m2) was administered intravenously on d1
Study NCT02987244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: epirubicin (70mg/m2)was administered intravenously on d1;
Study NCT02987244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: vindesine (4mg)was administered intravenously on d1;
Study NCT02987244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: etoposide (100mg) was administered intravenously on d1,2,3.
Study NCT02987244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: prednisone (60mg/m2)was administered intravenously by oral d1-5.
Study NCT01502670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FACBC Radiotracer
Description: Test radiotracer uptake in lung nodule
Study NCT01263444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% / timolol 0.5% Fixed Combination
Study NCT04263077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 100% TENSION GROUP
Description: Kinesiotape will be applied to the lateral epicondyle region with 100% tension.
Study NCT02695901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 0.12% (PerioGard®)
Description: At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%). Plaque indices will be recorded at baseline, day 4, and day 7.
Study NCT01263444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Habitual prostaglandin monotherapy
Description: Topical ocular therapy used daily as prescribed
Study NCT01781624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Oral Nutritional Supplement
Description: Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
Study NCT03504267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Education and Resources
Description: The intervention involves receiving evidence-based educational brochures as well as a list of local facilities where the participant can work out at no-cost to them,
Study NCT03365336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyherbal formulation
Description: Each Flu Care consist of 350 mg of polyherbal component
Study NCT03365336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75mg
Description: All the participant has to take 75 mg of oseltamivir for five days.
Study NCT03365336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir 75mg
Description: All the participant has to take 75 mg of oseltamivir for five days.
Study NCT03907449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Preview Rapid Strep A test
Description: Rapid assay for the detection of type A streptococcal infection of the throat.
Study NCT01749800 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GVS
Description: A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.
Study NCT01749800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GVS
Description: A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.
Study NCT02729311 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist control
Description: After engaging in usual activities for 12 weeks, the Waitlist control group participates in the Paired PLIÉ program.
Study NCT02695901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle solution of M. alternifolia oil (0.3%).
Description: At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.
Study NCT00993200 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: warfarin pharmacogenetic dosing
Description: Warfarin pharmacogenetic dosing incorporated into a validated clinical algorithm displayed in a computer (PERMIT) management interface
Study NCT00993200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Usual care warfarin dosing
Study NCT00795860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss - diet only
Description: Subjects adhere to a reduced calorie diet until they lose exactly 12% of their initial body weight. After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
Study NCT00795860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss plus exercise
Description: Subjects adhere to a reduced calorie diet and perform 4 session of endurance exercise training per week until they lose exactly 12% of their initial body weight. Exercise training consists of stationary bicycle exercise. the exercise duration and intensity ramp up over the first few weeks of training until subjects exercise 45 min per session at an intensity of 85% of their maximal heart rate. 3 of the 4 exercise session each week are supervised by an Exercise physiologist. After they achieve the 12% weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
Study NCT00842608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced exposure to anticholinergics
Description: Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.~Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can \& cannot receive Haldol
Study NCT00842608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced exposure to benzodiazepines
Description: Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation
Study NCT00842608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: 0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital
Study NCT00842608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium
Study NCT03380403 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PDT
Description: clinical treatment of infected diabetic foot
Study NCT02767154 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ringer-Acetate and Mannitol
Description: Currently clinic standard for priming the CPB circuit.
Study NCT02885181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9876
Description: One tablet administered orally once daily
Study NCT02885181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Two tablets administered orally once daily
Study NCT02885181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9876 placebo
Description: One tablet administered orally once daily
Study NCT02885181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-9876 placebo
Description: One tablet administered orally once daily
Study NCT02885181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib placebo
Description: Two tablets administered orally once daily
Study NCT02885181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgotinib placebo
Description: Two tablets administered orally once daily
Study NCT02885181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Background therapy with methotrexate administered orally or parenterally once weekly
Study NCT03380403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: antibiotics and or surgical debridment
Study NCT01991769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 47 min moderate intensity training
Study NCT01991769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 47 min moderate intensity training
Study NCT01749800 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham GVS
Description: Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.
Study NCT01749800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham GVS
Description: Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.
Study NCT01749800 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Armeo Spring
Description: A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.
Study NCT01749800 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Armeo Spring
Description: A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.
Study NCT03477669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chamomile/probiotic arm
Description: Caregivers will administer 5 drops of the study product once a day with a feeding at mid-day.
Study NCT03477669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of chamomile/probiotic arm
Description: Caregivers will administer 5 drops of the placebo study product once a day with a feeding at mid-day.
Study NCT01991769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise healthy volunteers
Study NCT01991769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise healthy volunteers
Study NCT01991769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control; no exercise training
Study NCT01991769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control; no exercise training
Study NCT03305575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Description: The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia.
Study NCT03305575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia.
Study NCT04214041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous fat grafting
Description: A fat graft will be aspirated from the abdomen under local anaesthesia and processed using the Microfat grafting technique. Afterwards the fat graft will be injected in the previously created pouch at the recipient site. Then the pouch will be closed using interrupted sutures 5-0 vicryl.
Study NCT04214041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-epithelial connective tissue graft
Description: A subepithelial connective tissue graft of a size that corresponds to that of the defect will be harvested from the palate using the trap door technique. The donor site will be closed using cross horizontal sling sutures and interrupted sutures 4-0 vicryl. Subsequently, the graft will be inserted in the previously created pouch at the recipient site and secured to the flap using vicryl sutures 5-0. Then the pouch will be closed using interrupted sutures.
Study NCT02377271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: treatment by bosentan or placebo is randomized , 125 mg twice a day
Study NCT02034201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine
Study NCT02034201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00794378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine (Clarinex)
Description: Each subject received 5 mL of desloratadine syrup one time
Study NCT02377271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: treatment by bosentan or placebo is randomized
Study NCT00794378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec)
Description: Each subject received 5 mL of cetirizine syrup
Study NCT03111589 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated influenza A (H1N1) virus vaccine
Description: All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
Study NCT03598283 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound/transient elastography
Description: The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
Study NCT03111589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza A (H1N1) virus vaccine
Description: All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
Study NCT01747044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: 100mg/day
Study NCT03111589 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.
Study NCT03111589 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.
Study NCT01747044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01691339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation
Description: 0.5 mL, Intramuscular
Study NCT01691339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation
Description: 0.1 mL, Intradermal
Study NCT01691339 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation
Description: 0.5 mL, Intramuscular
Study NCT02456441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The device current generator TENS used was  Neurodyn Portable Tens / Fes  of IBRAMED brand. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used. Through a chain of 1Hz, the aim is to correctly identify the tibial nerve. This position is confirmed with the rhythmic movement of the finger flexion. The frequency is then changed to 10Hz, the pulse width set at 200 microseconds and adjusted according to the intensity threshold for each patient, below motor threshold. This current generator also has a device, the VIF (variation in intensity and frequency) that aims to ease the accommodation of sensory receptors and enhance its effects. The application time is 30 minutes
Study NCT02456441 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The placebo group received an active current for 15 seconds by means of an apparatus also IBRAMED brand externally similar to that used in GI. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used.The application time for GP also was 30 minutes .
Study NCT02997774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooler dialysis
Description: Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)
Study NCT02997774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dialysis
Description: Having dialysis at a standard temperature (36.5 degrees Celsius)
Study NCT01870791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Weekly omegaven infusion in combination with EOX chemotherapy
Study NCT04660877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cheddar Cheese
Description: 20g of protein from cheddar cheese
Study NCT04660877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk
Description: 20g of protein from milk
Study NCT03794297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO
Study NCT03794297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03794297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03639987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: Administered as specified in the treatment arm.
Study NCT02885181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Background therapy with methotrexate administered orally or parenterally once weekly
Study NCT03639987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT03232632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET with 18 F-Flutemetamol
Description: PET with 18 F-Flutemetamol (Vizamyl ®)
Study NCT01769482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: 70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.
Study NCT01769482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01686100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No touch technique
Description: The vein graft is harvested with its surronding tissues.
Study NCT01686100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique
Description: The vein graft is stripped from its surrounding tissues.
Study NCT03048409 — intervention group
Intervention type: OTHER
Intervention: Enteral Formula
Description: Enteral feeding with a peptide-based formula.
Study NCT05024617 — intervention group
Intervention type: OTHER
Intervention: conservative treatment
Description: All patients had rehabilitation for a total of three months, including activity modification, splinting and exercises.